• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans.口服大麻二酚向Δ9-四氢大麻酚的转化似乎在人体内不会发生。
Cannabis Cannabinoid Res. 2017 May 1;2(1):81-86. doi: 10.1089/can.2017.0009. eCollection 2017.
2
Cannabinoids in Oral Fluid: Limiting Potential Sources of Cannabidiol Conversion to Δ9- and Δ8-Tetrahydrocannabinol.口腔液中的大麻素：限制大麻二酚转化为 Δ9-和 Δ8-四氢大麻酚的潜在来源。
J Anal Toxicol. 2021 Sep 17;45(8):807-812. doi: 10.1093/jat/bkab074.
3
Quantitation of Δ8-THC, Δ9-THC, Cannabidiol and 10 Other Cannabinoids and Metabolites in Oral Fluid by HPLC-MS-MS.高效液相色谱-串联质谱法检测口腔液中 Δ8-THC、Δ9-THC、大麻二酚和其他 10 种大麻素及其代谢物的定量分析。
J Anal Toxicol. 2022 Feb 14;46(1):76-88. doi: 10.1093/jat/bkaa184.
4
A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol.一项关于δ-8-四氢大麻酚相对于δ-9-四氢大麻酚和大麻二酚主观效果的众包调查研究。
Exp Clin Psychopharmacol. 2023 Apr;31(2):312-317. doi: 10.1037/pha0000565. Epub 2022 Apr 25.
5
Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.口服和蒸发型 CBD 以及以 CBD 为主的蒸发型大麻给药后，大麻二酚（CBD）、Δ9-四氢大麻酚（THC）及其代谢物的尿药代谢动力学特征。
J Anal Toxicol. 2022 May 20;46(5):494-503. doi: 10.1093/jat/bkab059.
6
Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, Δ9-Tetrahydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing With Three Oral Forms of Hemp Extract.三种口服形式的大麻提取物给药后犬血清中大麻二酚、大麻二酚酸、Δ9-四氢大麻酚、四氢大麻酚酸及相关代谢物的药代动力学
Front Vet Sci. 2020 Sep 4;7:505. doi: 10.3389/fvets.2020.00505. eCollection 2020.
7
Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats.低剂量的Δ9-四氢大麻酚和大麻二酚对大鼠可卡因诱导和苯丙胺诱导的条件性位置偏爱学习消退的影响。
Psychopharmacology (Berl). 2004 Sep;175(3):360-6. doi: 10.1007/s00213-004-1825-7.
8
Cannabidiol and Δ8-Tetrahydrocannabinol: Cannabinoids of Rising Interest and Concern.大麻二酚和Δ8-四氢大麻酚：备受关注且日益引发担忧的大麻素。
Forensic Sci Rev. 2023 Jan;35(1):27-45.
9
Will tetrahydrocannabinol be formed from cannabidiol in gastric fluid? An in vivo experiment.大麻二酚在胃液中会转化为四氢大麻酚吗？一项体内实验。
Int J Legal Med. 2023 Jan;137(1):79-87. doi: 10.1007/s00414-022-02896-w. Epub 2022 Oct 3.
10
Delta9-THC as a discriminative cue in pigeons: effects of delta8-THC, CBD, and CBN.Δ9-四氢大麻酚作为鸽子的辨别性线索：Δ8-四氢大麻酚、大麻二酚和大麻酚的影响。
Arch Int Pharmacodyn Ther. 1977 Jul;228(1):68-72.

引用本文的文献

1
Cannabidiol Modulates Emotional Function and Brain-Derived Neurotrophic Factor Expression in Middle-Aged Female Rats Exposed to Social Isolation.大麻二酚调节中年社交隔离雌性大鼠的情绪功能和脑源性神经营养因子表达。
Int J Mol Sci. 2023 Oct 23;24(20):15492. doi: 10.3390/ijms242015492.
2
THC-Reduced L.-How Does the Solvent Determine the Bioavailability of Cannabinoids Given Orally?THC 降低型大麻素-L-溶剂如何决定口服时大麻素的生物利用度？
Nutrients. 2023 Jun 6;15(12):2646. doi: 10.3390/nu15122646.
3
The history, evolution, and practice of cannabis and E-cigarette industries highlight necessary public health and public safety considerations.大麻和电子烟行业的历史、演变及实践凸显了必要的公共卫生和公共安全考量。
J Safety Res. 2023 Feb;84:192-203. doi: 10.1016/j.jsr.2022.10.019. Epub 2022 Nov 11.
4
The Dark Side of Cannabidiol: The Unanticipated Social and Clinical Implications of Synthetic Δ-THC.大麻素的阴暗面：合成 Δ-THC 带来的意想不到的社会和临床影响。
Cannabis Cannabinoid Res. 2023 Apr;8(2):270-282. doi: 10.1089/can.2022.0126. Epub 2022 Oct 19.
5
Quantification of Cannabis in Infused Consumer Products and Their Residues on Skin.含大麻消费品及其在皮肤上的残留物中大麻的定量分析。
ACS Pharmacol Transl Sci. 2022 Jul 18;5(8):642-651. doi: 10.1021/acsptsci.2c00077. eCollection 2022 Aug 12.
6
Statement on safety of cannabidiol as a novel food: data gaps and uncertainties.关于大麻二酚作为新型食品安全性的声明：数据缺口与不确定性。
EFSA J. 2022 Jun 7;20(6):e07322. doi: 10.2903/j.efsa.2022.7322. eCollection 2022 Jun.
7
Evaluation of cannabidiol's inhibitory effect on alpha-glucosidase and its stability in simulated gastric and intestinal fluids.大麻二酚对α-葡萄糖苷酶的抑制作用及其在模拟胃液和肠液中的稳定性评估。
J Cannabis Res. 2021 Jun 23;3(1):20. doi: 10.1186/s42238-021-00077-x.
8
Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.口服和蒸发型 CBD 以及以 CBD 为主的蒸发型大麻给药后，大麻二酚（CBD）、Δ9-四氢大麻酚（THC）及其代谢物的尿药代谢动力学特征。
J Anal Toxicol. 2022 May 20;46(5):494-503. doi: 10.1093/jat/bkab059.
9
Cannabis and Its Permissibility Status.大麻及其可允许状况。
Cannabis Cannabinoid Res. 2021 Dec;6(6):451-456. doi: 10.1089/can.2020.0017. Epub 2020 May 12.
10
Origin of Δ-Tetrahydrocannabinol Impurity in Synthetic Cannabidiol.合成大麻素中Δ-四氢大麻酚杂质的来源。
Cannabis Cannabinoid Res. 2021 Feb 12;6(1):28-39. doi: 10.1089/can.2020.0021. eCollection 2021.

本文引用的文献

1
An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.大麻二酚的安全性和副作用最新进展：临床数据及相关动物研究综述
Cannabis Cannabinoid Res. 2017 Jun 1;2(1):139-154. doi: 10.1089/can.2016.0034. eCollection 2017.
2
Conversion of Cannabidiol Following Oral Administration: Authors' Response to Grotenhermen et al. DOI: 10.1089/can.2016.0036.口服后大麻二酚的转化：作者对格罗滕赫尔门等人的回应。DOI: 10.1089/can.2016.0036。
Cannabis Cannabinoid Res. 2017 Jan 1;2(1):5-7. doi: 10.1089/can.2016.0038. eCollection 2017.
3
Even High Doses of Oral Cannabidol Do Not Cause THC-Like Effects in Humans: Comment on Merrick et al. 2016;1(1):102-112; DOI: 10.1089/can.2015.0004.即使高剂量口服大麻二酚也不会在人体产生类似四氢大麻酚的效果：对梅里克等人的评论。2016年；1(1):102 - 112；DOI: 10.1089/can.2015.0004
Cannabis Cannabinoid Res. 2017 Jan 1;2(1):1-4. doi: 10.1089/can.2016.0036. eCollection 2017.
4
Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid.在模拟胃液和生理液中鉴定大麻二酚的精神活性降解产物。
Cannabis Cannabinoid Res. 2016 Apr 1;1(1):102-112. doi: 10.1089/can.2015.0004. eCollection 2016.
5
Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy.大麻二酚的人体代谢产物：关于其形成、生物活性及治疗相关性的综述
Cannabis Cannabinoid Res. 2016 Mar 1;1(1):90-101. doi: 10.1089/can.2015.0012. eCollection 2016.
6
Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol.富含大麻二酚的大麻提取物致两名难治性癫痫儿童Δ9-四氢大麻酚中毒：改用纯化大麻二酚后完全缓解
Front Pharmacol. 2016 Sep 30;7:359. doi: 10.3389/fphar.2016.00359. eCollection 2016.
7
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.二型糖尿病患者使用大麻二酚和四氢大麻酚素对血糖和血脂参数的疗效和安全性：一项随机、双盲、安慰剂对照、平行分组的初步研究。
Diabetes Care. 2016 Oct;39(10):1777-86. doi: 10.2337/dc16-0650. Epub 2016 Aug 29.
8
Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.大麻二酚制剂作为新型治疗药物的现状与前景
Pharmacotherapy. 2016 Jul;36(7):781-96. doi: 10.1002/phar.1780.
9
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.大麻二酚治疗耐药性癫痫患者：一项开放标签的干预性试验。
Lancet Neurol. 2016 Mar;15(3):270-8. doi: 10.1016/S1474-4422(15)00379-8. Epub 2015 Dec 24.
10
Cannabinoids in the Treatment of Epilepsy.大麻素在癫痫治疗中的应用
N Engl J Med. 2015 Sep 10;373(11):1048-58. doi: 10.1056/NEJMra1407304.

口服大麻二酚向Δ9-四氢大麻酚的转化似乎在人体内不会发生。

A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans.

作者信息

Nahler Gerhard, Grotenhermen Franjo, Zuardi Antonio Waldo, Crippa José A S

机构信息

CIS Clinical Investigation Support GmbH, Wien, Austria.

Nova-Institut GmbH, Chemiepark Knapsack, Hürth, Germany.

出版信息

Cannabis Cannabinoid Res. 2017 May 1;2(1):81-86. doi: 10.1089/can.2017.0009. eCollection 2017.

DOI:10.1089/can.2017.0009
PMID:28861507
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5510776/
Abstract

Cannabidiol (CBD), a major cannabinoid of hemp, does not bind to CB1 receptors and is therefore devoid of psychotomimetic properties. Under acidic conditions, CBD can be transformed to delta9-tetrahydrocannabinol (THC) and other cannabinoids. It has been argued that this may occur also after oral administration in humans. However, the experimental conversion of CBD to THC and delta8-THC in simulated gastric fluid (SGF) is a highly artificial approach that deviates significantly from physiological conditions in the stomach; therefore, SGF does not allow an extrapolation to conditions. Unsurprisingly, the conversion of oral CBD to THC and its metabolites has not been observed to occur , even after high doses of oral CBD. In addition, the typical spectrum of side effects of THC, or of the very similar synthetic cannabinoid nabilone, as listed in the official Summary of Product Characteristics (e.g., dizziness, euphoria/high, thinking abnormal/concentration difficulties, nausea, tachycardia) has not been observed after treatment with CBD in double-blind, randomized, controlled clinical trials. In conclusion, the conversion of CBD to THC in SGF seems to be an artifact.

摘要

大麻二酚（CBD）是大麻的一种主要大麻素，不与CB1受体结合，因此没有拟精神病特性。在酸性条件下，CBD可转化为Δ9-四氢大麻酚（THC）和其他大麻素。有人认为，在人类口服后也可能发生这种情况。然而，在模拟胃液（SGF）中将CBD实验性转化为THC和Δ8-THC是一种高度人为的方法，与胃中的生理状况有很大偏差；因此，SGF不能外推至实际情况。不出所料，即使在高剂量口服CBD后，也未观察到口服CBD转化为THC及其代谢物的情况。此外，在双盲、随机、对照临床试验中，用CBD治疗后，未观察到THC或非常相似的合成大麻素纳布隆的典型副作用谱（如头晕、欣快感/兴奋、思维异常/注意力不集中、恶心、心动过速）。总之，在SGF中CBD向THC的转化似乎是一种假象。